Skip to main content
TipRanks
Go Ultimate75% OFF

Avicanna (0NN) AI Stock Analysis

0 Followers
DE:0NN

Avicanna

(Frankfurt:0NN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving ProfitabilityThe first positive adjusted EBITDA quarter indicates that cost discipline and stronger operating execution are beginning to improve the earnings profile. If maintained, recurring expense reductions and better margins could support a more credible path toward sustainable profitability over the next several quarters.
Negative Factors
Persistent Cash BurnNegative operating and free cash flow show that the business is not yet funding itself through operations, despite recent progress in adjusted EBITDA. Continued cash burn can limit investment capacity and increase dependence on external financing until profitability and working-capital performance improve.

Avicanna (0NN) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:0NN-70.41%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 9.27M
Dividend Yield
―
Average Volume (3M)
8,760
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.60
Revenue Growth
-7.46%
EPS Growth
-34.31%
Country
Germany
Employees
112
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Avicanna Business Overview & Revenue Model

Company Description

Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...

Avicanna Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-15.25%|Next Earnings Date:May 25, 2020
Earnings Call SentimentPositive

The call was broadly positive. Management highlighted the first positive adjusted EBITDA quarter, improving operating results, stronger gross margins year-over-year, reduced expenses, improved working capital, growth in proprietary and international revenue, the launch and expansion of the QUIX portfolio, and progress in clinical, pharmaceutical, and international initiatives. These positives were tempered by a 10% year-over-year revenue decline, lower gross profit, sequential gross-margin compression, negative operating cash flow, the impact of Veterans Affairs Canada reimbursement changes, licensing revenue variability, debt obligations, and the company's low market valuation.

Positive Updates

Ten-Year Milestone and Expanded Business Platform
Avicanna will reach its 10-year anniversary next week. The company has evolved into an international biopharmaceutical company with 68 commercial SKUs, 1 pharmaceutical product, several clinical programs, and established international commercial operations.

Negative Updates

Year-over-Year Revenue Decline
Q3 revenue declined 10% year-over-year to $5.7 million, primarily due to Veterans Affairs Canada reimbursement changes that reduced reimbursement for veteran patients by 29% effective April 1, along with lower licensing revenue.

Company Guidance

For Q4, management expects to continue the cost discipline, launch further QUIX SKUs across the Canadian market, improve the MyMedi percentage of sales, and generate “some early signals of international revenue growth”; it expects the majority of recent G&A savings to be recurring into Q4 and going into next year, expects to file an SR&ED claim every year going forward, and expects the Avicanna share of MyMedi sales to trend towards “40% to even 50% of the sales.” Management expects further SKU launches, margin efficiencies, and signals of growth going into Q4, early signals from SMGH this year and next year, significant pharmaceutical milestones going into 2027, and U.S. rescheduling “towards the end of this year or early next year.”

Avicanna Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0NN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS57NeutralCAD 27.77M-10.00-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:CWEBTSE:CWEB42NeutralCAD 66.59M-0.86-139.56%―-9.90%-35.35%
TSE:INNOTSE:INNO41NeutralCAD 7.42M-5.57-19.37%―-19.20%42.54%
TSE:CRDLTSE:CRDL38UnderperformCAD 177.37M-4.27-159.80%――19.57%
TSE:PCLOTSE:PCLO23UnderperformCAD 8.41M-2.4128.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%800%DE:0NNTSE:CWEBTSE:LABSTSE:PCLOTSE:CRDLTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:0NN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0NNAvicanna Inc0.05-0.10-66.67%
TSE:CWEBCharlotte's Web Holdings (OTC)0.240.1181.48%
TSE:LABSMedipharm Labs (Otc)0.07-0.01-7.14%
TSE:PCLOPharmacielo0.040.000.00%
TSE:CRDLCardiol Therapeutics Inc.1.470.085.76%
TSE:INNOInnocan Pharma Corporation1.65-14.05-89.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.